DERM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Journey Medical Corp (DERM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as the increased revenue and strong Q4 execution, the company's financial performance shows significant net income and EPS declines, and the technical indicators suggest a bearish trend. The lack of recent news, congress trading data, and proprietary trading signals also limits the appeal of this stock as an immediate buy.
The MACD is positive and expanding, indicating some bullish momentum, but the RSI is neutral at 43.691, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential in the near term, with resistance at 5.366 and support at 4.64.
Revenue increased by 18.05% YoY in Q4 2025, and gross margin improved slightly to 59.54%. Analyst B. Riley raised the price target to $12 and maintained a Buy rating, citing strong Q4 execution and prescription volume growth.
Net income dropped significantly by -181.99% YoY, and EPS declined by -171.43% YoY. The stock shows a bearish trend in technical indicators, and there is no recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue increased to $16.08M, up 18.05% YoY, but net income dropped to -$1.247M (-181.99% YoY), and EPS fell to -0.05 (-171.43% YoY). Gross margin improved slightly to 59.54%.
B. Riley raised the price target to $12 from $11 and maintained a Buy rating, citing strong Q4 execution and prescription volume growth.
